For drug discovery teams advancing complex peptides, small molecules and new modalities, IRBM's expanded Purification…
The decision to advance a candidate is only as sound as the data behind it…
Rome, Italy — February 10, 2026 — IRBM, a leader in early drug discovery research,…
We’ve recently expanded our mass spectrometry and imaging capabilities with the installation of Bruker’s rapifleX® MALDI…
Prestigious bilingual publication highlights 30 standout companies shaping the future of Italian enterprise—from design and…
De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /originally distributed by PRNewswire/– IRBM, an…
Covalent inhibitors have become a key strategy in drug discovery, offering advantages such as prolonged…
At IRBM, we believe that scientific excellence thrives in environments where diverse perspectives are not…
On October 24, 2024, IRBM's CEO Matteo Liguori represented the organization at the G7 Ministerial…
The IRBM Group Achieves EcoVadis Gold Rating: Leading the Way in Sustainability in the Life…
Dublin, Ireland, and Rome, Italy, 20 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing…
This year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego showcased a…
